Mennear J H
School of Pharmacy, Campbell University, Buies Creek, North Carolina 27506.
Regul Toxicol Pharmacol. 1994 Dec;20(3 Pt 1):354-61. doi: 10.1006/rtph.1994.1080.
After 30 years of experience with human exposure to dichlorvos (DDVP) in the home, workplace, and sickroom, the U.S. EPA has published its intent to revoke the food additive registration of this cholinesterase-inhibiting insecticide. The basis for the Agency action is the result of the National Toxicology Program (NTP) toxicology and carcinogenesis study of DDVP in rats and mice (NTP Technical Report No. 342, September 1989). In those experiments the NTP considered the result in the female mouse portion of the study to afford unequivocal evidence of carcinogenicity. The NTP considered the interpretations of the male and female rat and the male mouse studies to be less than clear. Despite the NTP interpretation, the EPA considers the male rat data (increased incidence of mononuclear cell leukemia) to be sufficient to warrant the regulatory change. The purpose of this report is to summarize a review of the interpretation of the NTP data and to assess the predictive validity of the results relative to potential human health impact. Critical review of experimental data indicates that the evidence for a carcinogenic effect of DDVP in animals is equivocal. Further, DDVP possess no in vivo mutagenic activity in mammalian assay systems and it bears no significant structural similarity to known carcinogens. Therefore, a weight-of-the-evidence analysis leads to the conclusion that DDVP poses neither mutagenic nor carcinogenic risks to humans exposed under normal conditions of use of foreseeable conditions of misuse.
在美国环境保护局(EPA)积累了30年关于人类在家庭、工作场所和病房接触敌敌畏(DDVP)的经验之后,它发布了撤销这种抑制胆碱酯酶的杀虫剂食品添加剂注册的意向。该机构采取行动的依据是国家毒理学计划(NTP)对大鼠和小鼠进行的敌敌畏毒理学和致癌性研究结果(NTP技术报告第342号,1989年9月)。在那些实验中,NTP认为该研究中雌性小鼠部分的结果提供了明确的致癌证据。NTP认为雄性和雌性大鼠以及雄性小鼠研究的解释不够明确。尽管有NTP的解释,但EPA认为雄性大鼠的数据(单核细胞白血病发病率增加)足以证明有必要进行监管变更。本报告的目的是总结对NTP数据解释的综述,并评估结果相对于潜在人类健康影响的预测有效性。对实验数据的批判性审查表明,敌敌畏在动物体内的致癌作用证据并不明确。此外,敌敌畏在哺乳动物检测系统中没有体内诱变活性,并且它与已知致癌物没有显著的结构相似性。因此,证据权重分析得出的结论是,在正常使用条件或可预见的滥用条件下接触敌敌畏的人类既不会面临诱变风险也不会面临致癌风险。